Clinical trials: FAPI PET
Acute Myocardial Infarction (AMI)
Early Ga-68 FAPI PET/MR After Acute Myocardial Infarction
Acute myocardial infarction (AMI) initiates a complex myocardial repair process involving inflammation, fibroblast activation, and extracellular matrix remodeling, which may ultimately lead to adverse left ventricular remodeling…
- Trial name
- REMODEL-FAPI (NCT07684924)
- Testing
- 68Ga-FAPI-04 PET/MR
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Ankara University
Rectal Cancer, Lymph Node Metastases
Comparison of [68Ga]Ga-CTR-FAPI and 18F-FDG PET/MRI for Lymph Node Staging in Rectal Cancer
This is a prospective, single-center, diagnostic study designed to compare the accuracy of [68Ga]Ga-CTR-FAPI PET/MRI and [18]F-FDG PET/MRI for the detection of lymph node metastasis in patients with initially untreated…
- Conditions
- Rectal Cancer, Lymph Node Metastases, PET / MR
- Trial name
- PKUCH-R12 (NCT07552207)
- Testing
- PET/MRI with 18F-FDG and [68Ga]Ga-CTR-FAPI
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Neoplasms
Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts
PET / CT examination using [18F] FAPI-74 is performed on patients diagnosed with malignant tumor, and the pathological condition is determined by comparing with FDG-PET/CT examination of conventional diagnostic imaging.
- Trial name
- NCT05442151
- Testing
- PET/CT ([F-18]FAPI-74)
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Tadashi Watabe
Rheumatoid Arthritis
Clinical Study of 18F-FAPI-RGD PET/CT in Rheumatoid Arthritis
The goal of this observational study is to learn about 18F-FAPI-RGD PET/CT imaging in assessing rheumatoid arthritis disease activity. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.
- Trial name
- NCT05944198
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan Provincial People's Hospital
Cancer
18F-FAPI and 18F-FDG PET/CT in Patients With Various Types of Cancer
FAP is overexpressed in the cancer-associated fibroblasts (CAFs) of 90% epithelial carcinomas. Currently, 68Ga-fibroblast activation protein inhibitor (FAPI) has shown promising diagnostic value in many types of tumors.
- Trial name
- FAPI-VTC (NCT05485792)
- Testing
- 18F-FAPI PET/CT and 18F-FDG PET/CT
- Volunteers
- 200 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Locally Advanced Gastric Adenocarcinoma, STOMACH NEOPLASM
[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
The goal of this clinical trial is to learn if a new type of scan, FAPI-PET/CT, can help find metastases of gastric cancer. We want to know how well this scan works for this purpose and whether it is less burdensome for patients…
- Conditions
- Locally Advanced Gastric Adenocarcinoma, STOMACH NEOPLASM, Gastric Cancer, PET-CT
- Trial name
- PLASTIC-3 (NCT07018661)
- Testing
- [18F]FAPI-74 PET/CT, [18F]-FAPI-74
- Where
- 10 sites in Netherlands
- Volunteers
- 250 people
- Sponsor
- Leiden University Medical Center
Carotid Artery Plaque, Ischemic Stroke
18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaque Vulnerability: A Clinical Study in Carotid Artery Plaque Patients
Carotid atherosclerotic plaque rupture is the main cause of ischemic stroke attacks, and early and precise assessment of plaque vulnerability can prevent ischemic stroke.
- Conditions
- Carotid Artery Plaque, Ischemic Stroke, PET / MR
- Trial name
- NCT07004673
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)
Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers
The goal of this prospective observational study is to evaluate whether Gallium-68 Fibroblast Activation Protein Inhibitor (FAPI) PET/CT can improve detection, staging, and recurrence assessment in adult patients (≥18 years) with…
- Trial name
- FAPi-2 (NCT07337850)
- Testing
- gallium-68-Fibroblast Activation Protein Inhibitor
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Centre
Crohn Disease
A Non-invasive Diagnostic Model for Intestinal Fibrosis in Crohn's Disease Based on 18F-FAPI PET Imaging
Crohn's disease (CD) is a chronic transmural inflammatory bowel disease. Prolonged episodes of inflammation can lead to intestinal fibrosis, leading to intestinal stenosis and obstruction.
- Trial name
- NCT05824962
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xiao Chen
Esophageal Cancer, Gastric Cancer (GC)
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric…
- Conditions
- Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- Trial name
- FAPI-GO (NCT07217704)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 19 sites in United States
- Volunteers
- 200 people
- Sponsor
- SOFIE
Thyroid Pathology, Head and Neck Cancer (H&N)
FAPI PET Imaging - An Exploratory Study
This study is testing a new imaging tracer called [18F]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions…
- Conditions
- Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis
- Trial name
- FAPIPET (NCT07705074)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 5 sites in Switzerland
- Volunteers
- 770 people
- Sponsor
- Martin Huellner
Breast Cancer
Rationale and Trial Design of PFB-03 Study: Diagnostic Performance and Clinical Application of 18F-FAPI-PET/CT for Detecting Axillary Lymph Node Metastasis in Breast Cancer Patients After Neoadjuvant Therapy
Axillary lymph node (ALN) status is a crucial prognostic factor in breast cancer. Accurate, non-invasive methods for evaluating axillary lymph node metastasis after neoadjuvant therapy (NAT) are needed to optimize surgical…
- Trial name
- NCT07012707
- Volunteers
- 172 people
- Sponsor
- Peking Union Medical College Hospital
Tumor, Solid, Positron-Emission Tomography
68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG
As a new dual receptor (integrin αvβ3 and FAP) targeting PET radiotracer, 68Ga-FAPI-RGD is promising as an excellent imaging agent applicable to various cancers.
- Trial name
- NCT05543317
- Testing
- 18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
Sarcoma
Paediatric Sarcoma, Hybrid Imaging & FAPI - Raising the Diagnostic Standard for Paediatric Sarcoma Patients, Combining Novel Radiotracer FAPI and Whole-body PET/MRI
The goal of this clinical trial is to evaluate [68Ga]FAPI-46 whole-body PET/MRI as a diagnostic tool to improve tumour lesion examination at primary staging, during treatment control and at relapse in paediatric sarcoma patients.
- Trial name
- PsiFI (NCT07861217)
- Testing
- FAPI tracer
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Tumor Positron-Emission Tomography
A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study
Both fibroblast activation protein (FAP)-targeted imaging and somatostatin receptors (SSTR)-targeted imaging were the promising imaging modalities for the diagnosis of primary and metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT05990998
- Testing
- 68Ga-DOTATATE and 68Ga-FAPI
- Where
- China
- Volunteers
- 38 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Lung Cancer
Comparison of 68Ga-FAPI-46 PET and 18F-FDG PET in Lung Cancer
This is a prospective, single-center, single arm, open label study to evaluate the performance of 68Ga-FAPI-46 for the diagnosis of primary and metastatic lesions of lung cancer with comparison to 18F-FDG PET.
- Trial name
- NCT05617742
- Testing
- 68Ga-FAPI-46
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- Chang Gung Memorial Hospital
Pancreatic Cancer
68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer
This is a preliminary study of 68Ga-FAPI-FS PET/CT or PET/MR in patients with confirmed or suspicious pancreatic cancer. The goal is to determine the safety, biodistribution, and tumor uptake of 68Ga-FAPI-FS.
- Trial name
- NCT05875753
- Testing
- 68Ga-FAPI-FS PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cancer, Adenocarcinoma Pancreas
FAPi PET in Pancreatic Ductal Adenocarcinoma
Pancreatic adenocarcinoma commonly referred to as pancreatic cancer is a cancer which is known to involve the pancreas and the surrounding structures like blood vessels, which makes it an aggressive cancer.
- Trial name
- FAP-1 (NCT07342231)
- Testing
- Ga-68 FAPi PET/CT
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Hospital
Tumor, Solid, FAPI, PET/CT, Metastasis
Comparison of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT in Patients With Various Types of Cancer
To evaluate the potential usefulness of 68Ga-DOTA-2P(FAPI)2 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 68Ga-DOTA-FAPI-46…
- Trial name
- NCT04941872
- Testing
- 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT
- Where
- China
- Volunteers
- 7 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
SAPHO Syndrome
Characterizing SAPHO With 68Ga-FAPI PET/CT
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation.
- Trial name
- NCT04596462
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital